Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) Non Operating Income (2016 - 2025)

Anaptysbio (ANAB) has disclosed Non Operating Income for 10 consecutive years, with -$66.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 447.83% year-over-year to -$66.4 million, compared with a TTM value of -$61.0 million through Dec 2025, down 402.71%, and an annual FY2025 reading of -$61.0 million, down 101.34% over the prior year.
  • Non Operating Income was -$66.4 million for Q4 2025 at Anaptysbio, down from $29.6 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $29.6 million in Q3 2025 and bottomed at -$66.4 million in Q4 2025.
  • Average Non Operating Income over 5 years is -$4.5 million, with a median of -$500.0 recorded in 2021.
  • The sharpest move saw Non Operating Income crashed 150300.0% in 2022, then surged 592100.0% in 2025.
  • Year by year, Non Operating Income stood at $1000.0 in 2021, then crashed by 41700.0% to -$416000.0 in 2022, then skyrocketed by 80.77% to -$80000.0 in 2023, then tumbled by 15050.0% to -$12.1 million in 2024, then tumbled by 447.83% to -$66.4 million in 2025.
  • Business Quant data shows Non Operating Income for ANAB at -$66.4 million in Q4 2025, $29.6 million in Q3 2025, and -$26.1 million in Q2 2025.